Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Amortization of Deferred Charges (2021)

Historic Amortization of Deferred Charges for ARS Pharmaceuticals (SPRY) over the last 1 years, with Q2 2021 value amounting to $1000.0.

  • ARS Pharmaceuticals' Amortization of Deferred Charges changed N/A to $1000.0 in Q2 2021 from the same period last year, while for Dec 2021 it was $2000.0, marking a year-over-year change of. This contributed to the annual value of $2000.0 for FY2021, which is 9354.84% down from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Amortization of Deferred Charges of $1000.0 as of Q2 2021.
  • ARS Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $1000.0 during Q1 2021, with a 5-year trough of $1000.0 in Q1 2021.